Fundraising FoxJocasta
Northbrook, US · Founded 2021 · 1 known investors
Find your way into Jocasta
Sign up to see every warm intro you have to Jocasta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Jocasta team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Jocasta Neuroscience is a biotechnology company developing JN-0413, a proprietary subcutaneous formulation of soluble α-Klotho protein aimed at treating age-related cognitive decline and neurodegenerative diseases such as mild cognitive impairment, Alzheimer's, and Parkinson's-related dementia. The company targets brain aging at its root cause and anticipates beginning human trials in early 2027.
Founders & leadership
Board
Investors · 1
How we know: funding news · trueventures.com · Not right? Tell us
Funding
SEC filings, press & company announcements$66.6M disclosed across 2 of 3 rounds · 2024–2025
- $35MSeries AAug 2025 · 4 sourcesSource ↗
▶$31.6MraisedNov 2024 · 20 investors · OtherRule 506(b)
- Jonathan JonasExecutive Officer
- Albert AgroExecutive Officer, Director
- Kevin RoseDirector
- Michael DavidsonExecutive Officer, Director
- Offering amount
- $40.1M
- Amount sold
- $31.6M
- Minimum investment
- $1
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Jocasta went on to found or lead other companies.
Frequently asked questions
- What does Jocasta do?
- Jocasta Neuroscience is a biotechnology company developing JN-0413, a proprietary subcutaneous formulation of soluble α-Klotho protein aimed at treating age-related cognitive decline and neurodegenerative diseases such as mild cognitive impairment, Alzheimer's, and Parkinson's-related dementia. The company targets brain aging at its root cause and anticipates beginning human trials in early 2027.
- Who are Jocasta's investors?
- Jocasta's investors include True Ventures.
- How much funding has Jocasta raised?
- Jocasta has disclosed $66.6M raised across 2 of its 3 known rounds.
- Where is Jocasta headquartered?
- Jocasta is headquartered in Northbrook, US.